Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.

about

Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.

Item

http://www.wikidata.org/entity/Q50893707

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Characterization of HER2 gene ...... t-field in situ hybridization.

@en

Characterization of HER2 gene ...... t-field in situ hybridization.

@nl

type

Item

label

Characterization of HER2 gene ...... t-field in situ hybridization.

@en

Characterization of HER2 gene ...... t-field in situ hybridization.

@nl

prefLabel

Characterization of HER2 gene ...... t-field in situ hybridization.

@en

Characterization of HER2 gene ...... t-field in situ hybridization.

@nl

P1476

Characterization of HER2 gene ...... ht-field in situ hybridization

@en

P2093

Guilherme Oliveira

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Breast cancer prognostic classification in the molecular era: the role of histological grade.

Preoperative assessment of prognostic factors in breast cancer.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Receptor conversion in distant breast cancer metastases

P2888

s00428-017-2189-9

P304

589-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00428-017-2189-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

471

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Schmitt

António Polónia

P577

2017-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28702778

http://www.w3.org/2001/XMLSchema#string